Appendix Table F52. Clinical outcomes after tolterodine vs. placebo in secondary data analyses

Outcome	Reference	Dose	Events/ randomized to Duloxetine	Events/ randomized to placebo	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to t (95% CI)	Attributable events (95% CI)
Improvement in incontinence								
Improved perceptions of bladder condition	Appell, 1997[229]	1mg twice daily	50/121	69/176	1.05 (0.80; 1.40)	0.02 (-0.09; 0.13)		
Improved perceptions of bladder condition	Appell, 1997[229]	2mg twice daily	246/474	69/176	1.32 (1.08; 1.62)	0.13 (0.04; 0.21)	8 (5; 24)	127 (42; 212)
Treatment response (primary and secondary efficacy endpoints)	Sand, 2009[372]	4mg daily	140/227	167/430	1.59 (1.36; 1.86)	0.23 (0.15; 0.31)	4 (3; 7)	228 (150; 307)
Perceived improvement in bladder symptoms	Freeman, 2003[290]	4mg once daily	247/398	180/374	1.19 (1.04; 1.37)	0.09 (0.02; 0.16)	11 (6; 48)	89 (21; 156)
Perceived improvement in bladder symptoms in females	Freeman, 2003[290]	4mg once daily	250/398	181/374	1.30 (1.14; 1.48)	0.14 (0.07; 0.21)	7 (5; 13)	144 (75; 214)
Global self-evaluation of treatment: “much benefit”	Freeman, 2003[290]	4mg once daily	171/398	90/374	1.53 (1.24; 1.88)	0.16 (0.09; 0.23)	6 (4; 12)	158 (86; 231)
Global self-evaluation of treatment: much benefit	Freeman, 2003[290]	4mg once daily	172/398	88/374	1.84 (1.48; 2.28)	0.20 (0.13; 0.26)	5 (4; 8)	197 (132; 262)
Treatment failure								
No change in urgency perception scale score	Freeman, 2003[290]	4mg once daily	203/398	212/374	0.90 (0.79; 1.03)	-0.06 (-0.13; 0.01)		
Decrease in urgency perception scale score	Freeman, 2003[290]	4mg once daily	22/398	44/374	0.47 (0.29; 0.77)	-0.06 (-0.10; -0.02)	-16 (-44; -10)	-62 (-102; -23)
Global self-evaluation of treatment: little benefit	Freeman, 2003[290]	4mg once daily	138/398	118/374	1.10 (0.90; 1.34)	0.03 (-0.04; 0.10)		
Global self-evaluation of treatment: no benefit	Freeman, 2003[290]	4mg once daily	88/398	168/374	0.49 (0.40; 0.61)	-0.23 (-0.29; -0.16)	-4 (-6; -3)	-228 (-293; -163)

Appendix Table F52. Clinical outcomes after tolterodine vs. placebo in secondary data analyses (continued)

Outcome	Reference	Dose	Events/ randomized to Duloxetine	Events/ randomized to placebo	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to t (95% CI)	Attributable events (95% CI)
Treatment discontinuation								
Withdrawal	Freeman, 2003[290]	4mg once daily	173/398	118/374	1.38 (1.14; 1.66)	0.12 (0.05; 0.19)	8 (5; 19)	119 (51; 187)
Withdrawal	Appell, 1997[229]	1mg twice daily	7/121	17/176	0.60 (0.26; 1.40)	-0.04 (-0.10; 0.02)		
Discontinued prematurely	Chapple, 2008 [260]	4mg daily	9/290	6/283	1.46 (0.53; 4.06)	0.01 (-0.02; 0.04)		
Withdrawal due to AE	Appell, 1997[229]	1mg twice daily	2/121	9/176	0.32 (0.07; 1.47)	-0.03 (-0.07; 0.01)		
Withdrawal due to AE	Appell, 1997[229]	2mg twice daily	38/474	9/176	1.57 (0.77; 3.18)	0.03 (-0.01; 0.07)		
Adverse effects								
Abdominal pain	Freeman, 2003[290]	4mg once daily	16/398	6/374	2.51 (0.99; 6.34)	0.02 (0.00; 0.05)	41 (21; 964)	24 (1; 47)
Adverse events	Appell, 1997[229]	1mg twice daily	94/121	164/176	0.83 (0.75; 0.92)	-0.15 (-0.24; -0.07)	-6 (-14; -4)	-155 (-238; -72)
Adverse events	Appell, 1997[229]	2mg twice daily	351/474	164/176	0.79 (0.74; 0.85)	-0.19 (-0.25; -0.14)	-5 (-7; -4)	-191 (-246; -137)
Autonomic nervous system disorder	Appell, 1997[229]	1mg twice daily	35/121	37/176	1.38 (0.92; 2.05)	0.08 (-0.02; 0.18)		
Autonomic nervous system disorder	Appell, 1997[229]	2mg twice daily	204/474	37/176	2.05 (1.51; 2.78)	0.22 (0.15; 0.30)	5 (3; 7)	220 (145; 295)
Back pain	Sand, 2009[372]	4mg daily	1/227	1/430	1.89 (0.12; 30.14)	0.00 (-0.01; 0.01)		
Cardiac dysfunction	Appell, 1997[229]	2mg twice daily	4/474	3/176	0.50 (0.11; 2.19)	-0.01 (-0.03; 0.01)		

Appendix Table F52. Clinical outcomes after tolterodine vs. placebo in secondary data analyses (continued)

Outcome	Reference	Dose	Events/ randomized to Duloxetine	Events/ randomized to placebo	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to t (95% CI)	Attributable events (95% CI)
Cardiovascular adverse events	Appell, 1997[229]	1mg twice daily	15/121	14/176	1.56 (0.78; 3.11)	0.04 (-0.03; 0.12)		
Cardiovascular adverse events	Appell, 1997[229]	2mg twice daily	20/474	14/176	0.53 (0.27; 1.03)	-0.04 (-0.08; 0.01)		
Constipation	Chapple, 2008 [260]	4mg daily	8/290	4/283	1.95 (0.59; 6.41)	0.01 (-0.01; 0.04)		
Constipation	Sand, 2009[372]	4mg daily	6/227	10/430	1.14 (0.42; 3.09)	0.00 (-0.02; 0.03)		
Constipation	Freeman, 2003[290]	4mg once daily	23/398	16/374	1.35 (0.73; 2.52)	0.02 (-0.02; 0.05)		
Cough	Sand, 2009[372]	4mg daily	5/227	3/430	3.16 (0.76; 13.09)	0.02 (-0.01; 0.04)		
Diarrhea	Sand, 2009[372]	4mg daily	3/227	10/430	0.57 (0.16; 2.04)	-0.01 (-0.03; 0.01)		
Diarrhea	Freeman, 2003[290]	4mg once daily	8/398	7/374	1.07 (0.39; 2.93)	0.00 (-0.02; 0.02)		
Dizziness	Sand, 2009[372]	4mg daily	4/227	9/430	0.84 (0.26; 2.70)	0.00 (-0.03; 0.02)		
Dose reduction in case of intolerance	Appell, 1997[229]	2mg twice daily	43/474	7/176	2.28 (1.05; 4.98)	0.05 (0.01; 0.09)	20 (11; 82)	51 (12; 90)
Dry eye	Chapple, 2008 [260]	4mg daily	1/290	0/283	2.93 (0.12; 71.57)	0.00 (-0.01; 0.01)		
Dry eye	Sand, 2009[372]	4mg daily	1/227	0/430	5.67 (0.23; 138.65)	0.00 (-0.01; 0.02)		
Dry mouth	Chapple, 2008 [260]	4mg daily	49/290	20/283	2.39 (1.46; 3.92)	0.10 (0.05; 0.15)	10 (7; 22)	98 (46; 151)
Dry mouth	Sand, 2009[372]	4mg daily	37/227	32/430	2.19 (1.40; 3.42)	0.09 (0.03; 0.14)	11 (7; 29)	89 (35; 143)
Dry mouth	Freeman, 2003[290]	4mg once daily	95/398	28/374	3.19 (2.14; 4.74)	0.16 (0.11; 0.21)	6 (5; 9)	164 (114; 213)

Appendix Table F52. Clinical outcomes after tolterodine vs. placebo in secondary data analyses (continued)

Outcome	Reference	Dose	Events/ randomized to Duloxetine	Events/ randomized to placebo	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to t (95% CI)	Attributable events (95% CI)
Dry throat	Chapple, 2008 [260]	4mg daily	3/290	0/283	6.83 (0.35; 131.66)	0.01 (0.00; 0.02)		
Dry throat	Sand, 2009[372]	4mg daily	2/227	0/430	9.45 (0.46; 196.04)	0.01 (-0.01; 0.02)		
Fatigue	Chapple, 2008 [260]	4mg daily	10/290	1/283	9.76 (1.26; 75.74)	0.03 (0.01; 0.05)	32 (19; 113)	31 (9; 53)
Fatigue	Sand, 2009[372]	4mg daily	7/227	2/430	6.63 (1.39; 31.65)	0.03 (0.00; 0.05)	38 (20; 358)	26 (3; 50)
Gastrointestinal disorder	Appell, 1997[229]	1mg twice daily	27/121	48/176	0.82 (0.54; 1.23)	-0.05 (-0.15; 0.05)		
Gastrointestinal disorder	Appell, 1997[229]	2mg twice daily	123/474	48/176	0.95 (0.72; 1.27)	-0.01 (-0.09; 0.06)		
Headache	Sand, 2009[372]	4mg daily	13/227	18/430	1.37 (0.68; 2.74)	0.02 (-0.02; 0.05)		
Headache	Freeman, 2003[290]	4mg once daily	23/398	14/374	1.54 (0.81; 2.95)	0.02 (-0.01; 0.05)		
Increased alanine aminotransferase	Chapple, 2008 [260]	4mg daily	0/290	1/283	0.33 (0.01; 7.95)	0.00 (-0.01; 0.01)		
Moderate or severe dry mouth	Appell, 1997[229]	1mg twice daily	5/121	11/176	0.66 (0.24; 1.85)	-0.02 (-0.07; 0.03)		
Moderate or severe dry mouth	[229]	2mg twice daily	81/474	11/176	2.73 (1.49; 5.01)	0.11 (0.06; 0.16)	9 (6; 17)	108 (59; 158)
Nasopharyngitis	Chapple, 2008 [260]	4mg daily	10/290	7/283	1.39 (0.54; 3.61)	0.01 (-0.02; 0.04)		
Nasopharyngitis	Sand, 2009[372]	4mg daily	8/227	12/430	1.26 (0.52; 3.04)	0.01 (-0.02; 0.04)		
Nausea	Chapple, 2008 [260]	4mg daily	6/290	1/283	5.86 (0.71; 48.33)	0.02 (0.00; 0.03)		
Nausea	Sand, 2009[372]	4mg daily	3/227	5/430	1.14 (0.27; 4.71)	0.00 (-0.02; 0.02)		

Appendix Table F52. Clinical outcomes after tolterodine vs. placebo in secondary data analyses (continued)

Outcome	Reference	Dose	Events/ randomized to Duloxetine	Events/ randomized to placebo	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to t (95% CI)	Attributable events (95% CI)
Nausea	Freeman, 2003[290]	4mg once daily	5/398	5/374	0.94 (0.27; 3.22)	0.00 (-0.02; 0.02)		
Palpitations	Appell, 1997[229]	1mg twice daily	8/121	4/176	2.91 (0.90; 9.45)	0.04 (-0.01; 0.09)		
Palpitations	Appell, 1997[229]	2mg twice daily	2/474	4/176	0.19 (0.03; 1.00)	-0.02 (-0.04; 0.00)		
Serious adverse events	Appell, 1997[229]	2mg twice daily	19/474	5/176	1.41 (0.53; 3.72)	0.01 (-0.02; 0.04)		
URI	Sand, 2009[372]	4mg daily	2/227	9/430	0.42 (0.09; 1.93)	-0.01 (-0.03; 0.01)		
Urinary tract infection	Freeman, 2003[290]	4mg once daily	7/398	12/374	0.55 (0.22; 1.38)	-0.01 (-0.04; 0.01)		
UTI	Sand, 2009[372]	4mg daily	4/227	17/430	0.45 (0.15; 1.31)	-0.02 (-0.05; 0.00)		
Dry mouth	Freeman, 2003[290]	4mg once daily	15/398	7/374	2.01 (0.83; 4.88)	0.02 (0.00; 0.04)		